Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996502 | 1.00 | ABCB1 (0.51) | ABCB1MCL1P2RX7GPR119NR1H2 | |
| SCHEMBL9067588 | 1.00 | ABCB1 (0.51) | ABCB1MCL1P2RX7GPR119NR1H2 | |
| SCHEMBL21996496 | 0.91 | GPR119 (0.43) | ABCB1MCL1P2RX7GPR119 | |
| SCHEMBL28619216 | 0.88 | BDKRB2 (0.45) | ABCB1BDKRB2 | |
| SCHEMBL21996529 | 0.87 | ABCB1 (0.40) | ABCB1MCL1GPR119NR1H2NR1H3 | |
| SCHEMBL12460552 | 0.87 | HSD11B1 (0.40) | ABCB1MCL1GPR119 | |
| SCHEMBL3248153 | 0.87 | ABCB1 (0.54) | ABCB1MCL1GPR119NR1H2NR1H3 | |
| SCHEMBL29669464 | 0.87 | ABCB1 (0.54) | ABCB1MCL1GPR119NR1H2NR1H3 | |
| SCHEMBL1366652 | 0.85 | CYP2D6 (0.42) | MCL1GPR119 | |
| SCHEMBL1366650 | 0.85 | CYP2D6 (0.42) | MCL1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4197538-A1 | EGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-06-21 | — | — | EP | disclosed |
| EP-4183395-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2020145374-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | ABCB1 556/4885MCL1 2441/4885P2RX7 3283/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | ABCB1 820/4885MCL1 157/4885P2RX7 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.